Astellas Pharma Canada Inc. is proud to announce that VYLOY® (zolbetuximab) is now funded by the Ontario Drug Benefit Program under the New Drug Funding Program and in Quebec through the Liste des médicaments - Établissements de la RAMQ. VYLOY is funded as a first-line treatment for adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are claudin (CLDN) 18.2 positive as determined by a validated test in both provinces.
Health Canada granted Astellas market authorization of VYLOY in December 2024. The decision to reimburse VYLOY in Quebec and Ontario is a milestone towards making this important therapy available to patients.
Full article: newswire.ca
